Developing a high fibre carbonated soft drink with improved digestive tolerance and beneficial impacts on the gut microbiome: FUNKi-2.0

开发一种高纤维碳酸软饮料，可改善消化耐受性并对肠道微生物群产生有益影响：FUNKi-2.0

• 批准号: 10066535
• 金额: $ 22.47万
• 依托单位: FUNKI DRINKS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10066535
• 关键词: Developing; fibre; carbonated; soft; drink

Our vision is to develop a novel carbonated soft drink fortified with a fibre-blend with evidence-based benefits to gut microbes that offers a tasty, convenient and affordable way for the UK to easily achieve their recommended fibre intake of 30g each day.An initial assessment of the current carbonated drink formulation (FUNKi-1.0) on the gut microbiome using advanced _in vitro_ colonic fermentation models at Quadram Institute (QI) will identify an optimal fibre-blend for reformulation. This project will enable FUNKi to launch the UK's first carbonated soft drink fortified with a fibre-blend (FUNKi-2.0) that has proven digestive tolerance, benefits to gut microbes and potential to improve human health.FUNKi-2.0 will enable consumers to increase their fibre intake in a novel and innovative way that is convenient. Eating plenty of fibre is associated with lower risks of heart disease, stroke, type 2 diabetes and bowel cancer (NHS). Despite this, only 9% of the UK population achieve the recommended fibre intake of 30g per day! (FDF). The UK's appetite for CSDs is growing with annual consumption rising from 4.6 billion litres in 2021 to an estimated 4.9 billion litres in 2026\. This concept of providing optimal fibre intake in CSDs is powerful; if only 1% of the UK had one can of FUNKi-2.0 each day, that would mean 6.7 million more people would achieve their dietary fibre intake and reduce their risk of cardiovascular disease and obesity - helping to offset the 9% of all NHS spend on diet-related chronic disease and the estimated £49.9 billion wider societal costs predicted to arise from obesity by 2050\.

我们的愿景是开发一种新型碳酸软饮料，采用纤维混合物强化，对肠道微生物具有基于证据的益处，为英国提供一种美味、方便且经济实惠的方式，轻松实现每天建议的 30 克纤维摄入量。使用 Quadram 研究所 (QI) 先进的体外结肠发酵模型对当前碳酸饮料配方 (FUNKi-1.0) 对肠道微生物组的初步评估将确定 用于重新配制的最佳纤维混合物。该项目将使 FUNKi 能够推出英国首款强化纤维混合物的碳酸软饮料 (FUNKi-2.0)，该饮料已被证明具有消化耐受性、对肠道微生物有益以及改善人类健康的潜力。FUNKi-2.0 将使消费者能够以一种新颖、便捷的创新方式增加纤维摄入量。摄入大量纤维可以降低患心脏病、中风、2 型糖尿病和肠癌 (NHS) 的风险。尽管如此，只有 9% 的英国人口达到每天 30 克的建议纤维摄入量！ （FDF）。英国对碳酸饮料的需求不断增长，年消费量从 2021 年的 46 亿升增加到 2026 年的估计 49 亿升。在碳酸饮料中提供最佳纤维摄入量的这一概念非常强大。如果英国只有 1% 的人每天喝一罐 FUNKi-2.0，那就意味着将有 670 万人增加膳食纤维摄入量，并降低患心血管疾病和肥胖的风险 - 有助于抵消 9% 的 NHS 支出用于与饮食相关的慢性疾病，以及预计到 2050 年肥胖将带来 499 亿英镑的更广泛社会成本\。